Pfizer (PFE)
Pfizer Accounts Receivable: 14.18B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PFE Accounts Receivable Rankings
| Overall | 99th percentile | 35 of 3769 |
| Sector | 99th percentile | 1 of 442 in Healthcare |
| Industry | 94th percentile | 1 of 17 in Drug Manufacturers - Major |
PFE Accounts Receivable Range, Past 5 Years
| Minimum | 8.958B | Dec 2008 |
| Maximum | 15.75B | Sep 2011 |
| Average | 12.16B |
About Accounts Receivable
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
YCharts takes accounts receivable from the balance sheet of a company. It is reported net of allowance for bad debts.
Learn More
You may also be interested in these PFE related companies
PFE News
@SciGuy $DRRX I don't believe so; the fortunes of DURECT are tied to $PFE and Remoxy
about 29 minutes ago by SlownSteady
about 29 minutes ago by SlownSteady
@SCarolinaguy $DRRX licensed the drug to $PTIE; $PTIE licensed it to King and $PFE bought King; I think people might forget about $DRRX
about 49 minutes ago by SlownSteady
about 49 minutes ago by SlownSteady
@SlownSteady Sounds encouraging with $PFE supporting. What is the relationship? Surely their support would lead to approval
about 50 minutes ago by SCarolinaguy
about 50 minutes ago by SCarolinaguy
@SCarolinaguy $DRRX $PFE plans to resubmit the NDA. The company has other products; a recent filed trial triggered share price punishment
about 53 minutes ago by SlownSteady
about 53 minutes ago by SlownSteady
@SCarolinaguy $DRRX Only insiders know. CMC problems are usually resolved. $PFE will have new data and meet with the FDA
about 55 minutes ago by SlownSteady
about 55 minutes ago by SlownSteady
Still a Bear Market http://stks.co/41w8 $KFT $MCD $MRK $MSFT $PFE $KO
about 13 hours ago by LouisEbner
about 13 hours ago by LouisEbner
RT @Glopolon: Does it matter, they are next door to $PFE $AMRN /i live next to a lawyer. odds of being sued increased day they moved in. Hmm
about 3 days ago by ITradeforMe
about 3 days ago by ITradeforMe
RT @Glopolon $AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404L <Hmmmmmmmm!?$$$
about 3 days ago by Bleedblue
about 3 days ago by Bleedblue
$AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404H
about 3 days ago by Glopolon
about 3 days ago by Glopolon
@SomeGuy900 @christy155 $DRXX If $PFE gets a class 2 resubmission, they'll know in Q2/Q3 of next year; class one they'll know in Q1/Q2 '13
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 @christy155 $DRXX The $PFE discussions with the FDA should be in Q3; I imagine they will resubmit in early 2013
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 @christy155 The last comment from $DRRX management was that $PFE was getting ready to talk to the FDA about some more studies
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 @christy155 $DRRX I have no idea what's going on. It's gone up 20 cents since I bought in. Maybe $PFE will talk with the FDA
about 4 days ago by SlownSteady
about 4 days ago by SlownSteady
@SomeGuy900 $DRRX $PFE will meet with the FDA, likely this summer. The good thing about the NDA is that the CRL was a CMC issue, chemistry
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@rockchalk11 $ARNA Take a look at $DRRX; I bought it a few weeks ago at 72 cents. It's partnered, indirectly, with $PFE on Remoxy (a drug)
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
The Senate passed a bill that reauthorizes fees from drugmakers to fund the FDA. Likely to impact $PFE. http://stks.co/3zSI
about 5 days ago by ok123jump
about 5 days ago by ok123jump
@Urbane_Gorilla http://stks.co/3z5t $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist
about 6 days ago by biotech
about 6 days ago by biotech
Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
May 23, 7:31AM Street Insider
May 23, 7:31AM Street Insider
Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
May 18, 8:02AM Street Insider
May 18, 8:02AM Street Insider
Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients
May 18, 8:00AM Business Wire
May 18, 8:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PFE | 22.04 | -0.14 | -0.63% | 167.18B |
| PFD | 13.85 | -0.04 | -0.29% | |
| PFCB | 51.26 | -0.12 | -0.23% | 1.090B |
| PFBCD | 12.32 | +0.28 | +2.33% | |
| PFBC | 12.18 | -0.14 | -1.14% | 162.50M |
| PFA | 14.94 | +0.14 | +0.95% | |
| PEZ | 28.26 | -0.36 | -1.26% | |
| PEY | 9.06 | -0.09 | -0.98% | |
| PETS | 11.26 | -0.21 | -1.83% | 233.30M |
| PETM | 64.46 | -0.05 | -0.08% | 7.089B |